Literature DB >> 7237414

Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells.

V Raso, T Griffin.   

Abstract

Hybrid antibodies possessing one binding site for the toxic lectin ricin and a companion site directed against human immunoglobulin were constructed in vitro. This bifunctional reagent specifically attached to human lymphocyte surface immunoglobulin determinants and, thus situated, could simultaneously capture ricin molecules or its toxic A chain. Attachment of these components to the cell was revealed by specific fluorescein-labeled antibodies. Once concentrated at the target cell membrane, hybrid-bound toxin was subsequently released to function via its normal mechanism of biological action. It gained access to ribosomes, its intracellular target, and curtailed protein synthesis. Toxicity was not augmented for immunoglobulin-negative cells to which hybrid could not bind and free human immunoglobulin G could competitively block the enhanced effects observed for immunoglobulin-bearing cell lines. These results indicate that hybrid antibodies may be utilized to carry active agents within close proximity to the membrane of a specified cell type and thereby selectively enhance their effect.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7237414

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Yukiko Sone; Hiroko Kawaguchi; Shintaro Taki; Hiroki Hayashi; Takeshi Nakanishi; Mitsuo Umetsu; Yu Katayose; Michiaki Unno; Toshio Kudo; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

Review 3.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

4.  Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates.

Authors:  Vishwesh Patil; Keyur Gada; Rajiv Panwar; Alexandra Varvarigou; Stan Majewski; Andrew Weisenberger; Craig Ferris; Yared Tekabe; Ban-An Khaw
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05       Impact factor: 9.236

Review 5.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

6.  Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Ippei Shimomura; Shintaro Taki; Takeshi Nakanishi; Mitsuo Umetsu; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

Review 7.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

8.  Preparation and analysis of bifunctional immunoconjugates containing monoclonal antibodies OKT3 and BABR1.

Authors:  P D Foglesong; M A Winkler; J O Price; G D Marshall; S H Reagh; D A Bush; K S Hixson; W H West
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 9.  Targeting T cells with bispecific antibodies for cancer therapy.

Authors:  Lawrence G Lum; Archana Thakur
Journal:  BioDrugs       Date:  2011-12-01       Impact factor: 5.807

10.  Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells.

Authors:  Ryutaro Asano; Yuri Kuroki; Sachiko Honma; Mihoko Akabane; Shunsuke Watanabe; Shinzo Mayuzumi; Shuichi Hiyamuta; Izumi Kumagai; Koji Sode
Journal:  MAbs       Date:  2018-07-09       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.